Anamed Inc.
This article was originally published in Start Up
Executive Summary
While myopia is well served by laser vision correction techniques, using lasers to reshape the cornea is more technically challenging for hyperopia. For the 32 million hyperopic patients in the US, Anamed Inc. hopes to provide a new vision correction that is reversible, or "additive, not subtractive." Anamed's first product for vision correction is {PermaVision}, intracorneal lenses made of a proprietary biomaterial, for the treatment of myopia, presbyopia, astigmatism and hyperopia.
You may also be interested in...
Refractive Surgery
For the ultimate in convenience, hundreds of thousands of nearsighted and farsighted patients are turning to refractive surgery, or surgical vision correction procedures that promise a permanent alternative to glasses. New companies that wish to grab a portion of the $12 billion US market for vision correction are avoiding the crowded and competitive excimer laser business, with technologies that treat patients that LASIK (laser in-situ keratomileusis) doesn't serve well.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.